Tempest Therapeutics jumps onto Nasdaq in merger with struggling Millendo Therapeutics; Biohaven hits $100M milestone as it gears up for a late-stage study in migraine patients

Less than a month after landing a Big Pharma partner on one of its lead oncology programs, Tempest Therapeutics is backflipping onto Nasdaq through a reverse merger with Millendo Therapeutics.

Back in January, Millendo shut down the sole remaining early-stage study for its NK3R antagonist...

Click to view original post